Vivistim System for Stroke Rehab Awarded 2021 Gold Electrode Award

MicroTransponder® Inc., a medical device company developing solutions to restore independence and dignity for people suffering from neurological conditions that impair sensory and motor function, today announced that its Vivistim® Paired VNS™ System won the Neurotech Reports Gold Electrode Award for best new product. This announcement comes as MicroTransponder prepares for the first commercial implantation of Vivistim and as the company plans a 2022 sales launch in the United States.

The FDA-approved Vivistim System employs paired vagus nerve stimulation (VNS) that is activated during rehabilitation therapy to improve upper limb function for stroke survivors. Paired VNS therapy generates two to three times more hand and arm function than intense rehabilitation alone after six weeks of in-clinic therapy.

“We’re honored that Neurotech Reports recognized Vivistim as a breakthrough neurotechnology that addresses an unmet need for stroke survivors and their healthcare providers,” said Jordan Curnes, cofounder, president and chief operating officer of MicroTransponder. “As we begin commercialization of Vivistim, we remain committed to helping stroke survivors achieve improvements in their functional mobility while enhancing their quality of life. We are also proud to join the ranks of previous Neurotech Reports award winners, including Axonics®, Inc. and Saluda Medical™.”

The Vivistim System received FDA premarket approval (PMA) in August 2021, following a decade of preclinical research and a successful 108-person, multi-center, double-blinded, randomized controlled clinical trial that was peer-reviewed and published in The Lancet, a widely esteemed medical journal. MicroTransponder has also applied for the CE Mark for Vivistim.

“Our editors selected MicroTransponder’s Vivistim System as the best new product of 2021 because it breaks new ground in stroke neurorehabilitation and helps open the door for funding and commercialization of new neurorehabilitation systems,” said James Cavuoto, editor and publisher of Neurotech Reports, the leading source of news and analysis for the neurotechnology industry.

In preparation for its national sales launch, MicroTransponder is expanding its team and looking to hire experienced medical device professionals for sales, marketing, clinical, quality, regulatory, and operations positions.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”